Generic Medicine Info
Indications and Dosage
Bacterial conjunctivitis
Adult: As 0.6% susp: Instill 1 drop onto affected eye(s) tid, 4-12 hours apart, for 7 days.
Child: >1 year Same as adult dose.
Special Precautions
Children. Pregnancy and lactation.
Adverse Reactions
Significant: Hypersensitivity reactions, fungal or bacterial superinfection (prolonged use).
Eye disorders: Conjunctival redness, blurred vision, eye pain, eye irritation, eye pruritus.
Nervous system disorders: Headache.
Patient Counseling Information
Avoid use of contact lenses.
Description: Besifloxacin is a fluoroquinolone antibacterial which acts by inhibiting DNA synthesis in susceptible organisms via inhibition of both topoisomerase IV (essential during bacterial cell division) and DNA gyrase (essential for bacterial reproduction).
Excretion: Elimination half-life: Approx 7 hours.
Chemical Structure

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Database. Besifloxacin, CID=10178705, (accessed on Jan. 21, 2020)

Store between 15-25°C. Protect from light.
MIMS Class
Eye Anti-Infectives & Antiseptics
ATC Classification
S01AE08 - besifloxacin ; Belongs to the class of quinolone antiinfectives. Used in the treatment of eye infections.
Anon. Besifloxacin. AHFS Clinical Drug Information [online]. Bethesda, MD. American Society of Health-System Pharmacists, Inc. Accessed 05/04/2018.

Anon. Besifloxacin. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 05/04/2018.

Besivance Suspension (Bausch & Lomb Incorporated). DailyMed. Source: U.S. National Library of Medicine. Accessed 05/04/2018.

Buckingham R (ed). Besifloxacin. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 05/04/2018.

Disclaimer: This information is independently developed by MIMS based on Besifloxacin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in